A Prospective, Pre-market, Multi-center Evaluation of the Clinical Outcomes of the Insignia Hip Stem in Total Hip Arthroplasty (THA)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to evaluate the survivorship (revision rates) and patient reported outcomes (PROMs) following implantation of the Insignia hip stem in patients undergoing cementless total hip replacement surgery compared to currently available stems used for the same type of surgery. It is hypothesised the 2-year survivorship of the Insignia stem is noninferior to the benchmark survivorship of similar stems used in the same type of surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• The patient has signed the study specific, Human Research Ethics Committee (HREC) approved, Patient Information Consent Form for the use of the study device

• Primary non-inflammatory degenerative joint disease (including osteoarthritis or avascular necrosis) and/or rheumatoid arthritis

• The patient is a candidate for a primary cementless THA.

• Patients who are informed of the conditions of the study and are willing to participate for the length of the prescribed follow-up period.

Locations
Other Locations
Australia
St John of God Subiaco Hospital
RECRUITING
Subiaco
Contact Information
Primary
Holly Solomon
holly.solomon@stryker.com
+61405307762
Time Frame
Start Date: 2024-02-22
Estimated Completion Date: 2028-12
Participants
Target number of participants: 313
Treatments
Experimental: Intervention group
Insignia hip stem study group
Sponsors
Leads: Stryker Australia Pty Ltd.

This content was sourced from clinicaltrials.gov